Lord Abbett Health Care R6 holds a quantitatively derived Bronze Morningstar Medalist Rating. The rating reflects that it has scored better than the norm on factors Morningstar research associates with future outperformance relative to category peers.
Lord Abbett Health Care Fund Class R6 LHCVX
- NAV / 1-Day Return 23.86 / +2.01 %
- Total Assets 8.7M
-
Adj. Expense Ratio
0.680%
- Expense Ratio 0.650%
- Distribution Fee Level Low
- Share Class Type Retirement, Large
- Category Health
- Investment Style Mid Growth
- Min. Initial Investment 0
- Status Open
- TTM Yield 0.35%
- Turnover 91%
USD | NAV as of Jul 22, 2026 | 1-Day Return as of Jul 22, 2026, 12:11 AM GMT+0
Morningstar’s Analysis LHCVX
Will LHCVX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 43.0
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Eli Lilly and Co | 10.78 | 856,375 | Healthcare |
AstraZeneca PLC | 4.75 | 377,133 | Healthcare |
Gilead Sciences Inc | 4.48 | 355,836 | Healthcare |
Guardant Health Inc | 4.01 | 318,908 | Healthcare |
UnitedHealth Group Inc | 3.91 | 310,713 | Healthcare |
Natera Inc | 3.24 | 257,099 | Healthcare |
Johnson & Johnson | 3.20 | 254,398 | Healthcare |
CVS Health Corp | 3.13 | 248,739 | Healthcare |
argenx SE | 2.79 | 222,024 | Healthcare |
Galderma Group AG Registered Shares | 2.75 | 218,283 | Healthcare |